UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 15

 

 

CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION

UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934

OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934.

Commission File Number

000-23265

 

 

Salix Pharmaceuticals, Ltd.

(Exact name of registrant as specified in its charter)

 

 

8510 Colonnade Center Drive

Raleigh, North Carolina 27615

(919) 862-1000

(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

Common Stock, par value $0.001 per share

(Title of each class of securities covered by this Form)

None

(Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)

 

 

Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

 

Rule 12g-4(a)(1) x
Rule 12g-4(a)(2) ¨
Rule 12h-3(b)(1)(i) x
Rule 12h-3(b)(1)(ii) ¨
Rule 15d-6 ¨

Approximate number of holders of record as of the certification or notice date: 1

 

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this certification/notice to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: April 13, 2015

 

Salix Pharmaceuticals, Ltd.
By:

/s/ Robert R. Chai-Onn

Name: Robert R. Chai-Onn
Title:

Executive Vice President, General Counsel

and Corporate Secretary

Salix (NASDAQ:SLXP)
Historical Stock Chart
Von Mai 2024 bis Jun 2024 Click Here for more Salix Charts.
Salix (NASDAQ:SLXP)
Historical Stock Chart
Von Jun 2023 bis Jun 2024 Click Here for more Salix Charts.